Pandemic Perspectives: US FDA, NIH Tried To Be Flexible To Keep Rare Disease Trials Going

 
• By Derrick Gingery

Both federal agencies extended grants to help investigators adapt to the changes mandated by the COVID-19 pandemic.

government subsidy poverty compensation during covid-19 corona pandemic hand charity help economy crisis
NCATS Director Chris Austin said rare disease clinical trials will require rebuilding after the pandemic. • Source: Shutterstock

More from Clinical Trials

More from R&D